A novel biomarker, MRPS12 functions as a potential oncogene in ovarian cancer and is a promising prognostic candidate

Abstract

Ovarian cancer (OC) is the leading cause of gynecological cancer deaths. Extraordinary histologic and genetic heterogeneity presents as great hurdle to OC's diagnosis and treatment. MRPS12 (Mitochondrial Ribosomal Protein S12), encoding a 28S subunit protein, controls the decoding fidelity and susceptibility to aminoglycoside antibiotics. Our study aims to investigate the clinical significance and potential mechanism of MRPS12 in OC. Oncomine, Tumor Immune Estimation Resource database (TIMER), and GEPIA databases were utilized to explore the expression level of MRPS12 in OC and normal tissues. Kaplan–Meier plotter was used to evaluate the influence of MRPS12 expression on OC patients’ survival. The potential biologic function and immune infiltration of MRPS12 in OC were analyzed by GSEA (Gene set enrichment analysis) and TIMER database, respectively. MRPS12 was significantly highly expressed in OC (P < .05) compared with normal ovarian tissues. Its overexpression was also significantly related with poor overall survival in advanced FIGO stage (III+IV) patients, in serous OC and in those patients with TP53 mutation (P < .05). GSEA showed that HALLMARK_G2M_CHECKPOINT, BIOCARTA_CELLCYCLE_PATHWAY, HALLMARK_PI3K_AKT_MTOR_SIGNALING, BIOCARTA_P53_PATHWAY were significantly enriched in high-MRPS12-expression phenotype. MRPS12 expression was positively correlated with the infiltration of macrophages and neutrophils in OC. These results reveal that MRPS12 could function as a potential oncogene and serve as a promising prognostic candidate in OC.

A Personalized Genomics Approach of the Prostate Cancer

“…As illustrated here for one case of prostate cancer, and in previous papers on cases of papillary thyroid cancer [ 46 , 92 ] and clear cell renal cell carcinoma [ 35 , 93 ], GFP offers a comprehensive personalized alternative to the biomarkers approach to determine the cancer transcriptional identity (e.g., [ 112 ]) and explore gene therapy.…”

“…REV analysis pointed also to some interesting genes for oncogenomics. Thus, MRPS12 , the most stably expressed gene in “N”, is a potential prognostic candidate for ovarian cancer [ 92 ], while UXT the most unstably expressed gene in “N” is associated with advanced stages of gastric cancer [ 93 ]. ENTPD2 , the most stably expressed gene in “A” is a biomarker for lung [ 94 ] and hepatocellular [ 72 ] carcinomas, while USP31 , the most variably expressed gene in “A”, could be a potential target for sarcomas [ 95 ].…”

Systematic Analysis Identifies a Specific RNA-Binding Protein-Related Gene Model for Prognostication and Risk-Adjustment in HBV-Related Hepatocellular Carcinoma

“… Liu et al (2020) found that POLR2L displayed a correlation to survival duration and alternative splicing in lung squamous cell carcinoma patients. MRPS12 functioned as an oncogene and a prognostic candidate in ovarian carcinoma ( Qiu et al, 2021 ). DYNLL1 hypomethylation and upregulation was characterized by stage- and grade-dependent manners and correlated to unfavorable survival outcomes in HCC ( Berkel and Cacan, 2020 ).…”

Identification of the Upregulation of MRPL13 as a Novel Prognostic Marker Associated with Overall Survival Time and Immunotherapy Response in Breast Cancer

“…For example, MRPL15 is a new prognostic indicator and therapeutic target for epithelial ovarian cancer [ 26 ]. MRPS12 is a potential oncogene of ovarian cancer [ 27 ], while MRPL27 displays an adverse effect on the overall survival rate and disease-free survival rate of cholangiocarcinoma patients [ 28 ]. MRPL42 is activated by YY1 to promote the progression of lung adenocarcinoma [ 29 ].…”